Compounds > buthionine sulfoximine
Page last updated: 2024-08-22

buthionine sulfoximine and Multiple Myeloma

buthionine sulfoximine has been researched along with Multiple Myeloma in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19902 (20.00)18.7374
1990's2 (20.00)18.2507
2000's4 (40.00)29.6817
2010's2 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Augustyniak, D; Bartkowiak, A; Goffeau, A; Gonchar, M; Ko, YH; Lis, P; Majkowska-Skrobek, G; Pedersen, PL; Ułaszewski, S1
Kang, MH; Reynolds, CP; Singh, H; Tagde, A1
Boise, LH; Cai, Y; Croutch, C; Gutman, D; Lee, KP; Matulis, SM; Morales, AA; Yehiayan, L1
Jensen, GL; Meister, A1
Cai, X; Chen, G; Chen, S; Huang, X; Jia, P; Shen, Y; Wang, L; Wang, Z; Yang, J; Yu, Y; Zhang, X; Zhou, L; Zhou, Y1
Cai, X; Huang, X; Zhou, Y1
Grujić, M; Renko, M1
Awasthi, YC; Gupta, V; Medh, RD1
Bellamy, WT; Dalton, WS; Gleason, MC; Grogan, TM; Trent, JM1
Bellamy, WT; Dalton, WS; Dorr, RT; Meltzer, P1

Other Studies

10 other study(ies) available for buthionine sulfoximine and Multiple Myeloma

ArticleYear
Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy.
    Anti-cancer drugs, 2014, Volume: 25, Issue:6

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Buthionine Sulfoximine; Cell Survival; Glutathione; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Lactic Acid; Monocarboxylic Acid Transporters; Multiple Myeloma; Piperazines; Pyrimidines; Pyruvates; Symporters; Tumor Cells, Cultured

2014
The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.
    Blood cancer journal, 2014, Jul-18, Volume: 4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Buthionine Sulfoximine; Disease-Free Survival; Drug Synergism; Female; Humans; Melphalan; Mice; Mice, Nude; Multiple Myeloma; Random Allocation; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cysteine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Multiple Myeloma; Oxides

2009
Radioprotection of human lymphoid cells by exogenously supplied glutathione is mediated by gamma-glutamyl transpeptidase.
    Proceedings of the National Academy of Sciences of the United States of America, 1983, Volume: 80, Issue:15

    Topics: Acyltransferases; Buthionine Sulfoximine; Cell Line; Glutathione; Humans; Kinetics; Methionine Sulfoximine; Multiple Myeloma; Radiation-Protective Agents; T-Lymphocytes; Transglutaminases

1983
Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspase-3.
    Chinese medical journal, 2001, Volume: 114, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Caspase 3; Caspases; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Membrane Potentials; Mitochondria; Multiple Myeloma; Oxides; Tretinoin; Tumor Cells, Cultured

2001
[Mechanisms of arsenic trioxide-induced apoptosis in myeloma cells].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2001, Volume: 23, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Dithiothreitol; Drug Interactions; Humans; Interferon-alpha; Multiple Myeloma; Oxides; Tretinoin; Tumor Cells, Cultured

2001
Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions.
    Cancer letters, 2002, Aug-28, Volume: 182, Issue:2

    Topics: Aminopeptidases; Buthionine Sulfoximine; Cell Division; Cell Membrane; Enzyme Inhibitors; Humans; Hydroxamic Acids; K562 Cells; Leucine; Multiple Myeloma; Substrate Specificity; U937 Cells

2002
Reversal of melphalan resistance in vivo and in vitro by modulation of glutathione metabolism.
    Biochemical pharmacology, 1991, Jul-05, Volume: 42, Issue:2

    Topics: Buthionine Sulfoximine; Cell Survival; Drug Resistance; Glutathione; Glutathione Transferase; Humans; Melphalan; Methionine Sulfoximine; Multiple Myeloma; Neoplasm Transplantation; Tumor Cells, Cultured

1991
Development and characterization of a melphalan-resistant human multiple myeloma cell line.
    Cancer research, 1991, Feb-01, Volume: 51, Issue:3

    Topics: Alkylating Agents; Buthionine Sulfoximine; Cell Survival; DNA, Neoplasm; Drug Resistance; Glutathione; Humans; Karyotyping; Melphalan; Methionine Sulfoximine; Multiple Myeloma; Myeloma Proteins; Tumor Cells, Cultured

1991
Role of glutathione and its associated enzymes in multidrug-resistant human myeloma cells.
    Biochemical pharmacology, 1989, Mar-01, Volume: 38, Issue:5

    Topics: Buthionine Sulfoximine; Doxorubicin; Drug Resistance; Glutathione; Glutathione Peroxidase; Glutathione Transferase; Humans; Isoenzymes; Methionine Sulfoximine; Multiple Myeloma; Sulfhydryl Compounds; Tumor Cells, Cultured

1989